{
    "ticker": "SRLN",
    "name": "Sarepta Therapeutics, Inc.",
    "description": "Sarepta Therapeutics, Inc. is a biopharmaceutical company focused on the development of innovative gene therapies to treat rare diseases, particularly those caused by genetic mutations. Founded in 1980 and headquartered in Cambridge, Massachusetts, Sarepta is a leader in the field of precision medicine, with a strong emphasis on advancing therapies for Duchenne muscular dystrophy (DMD) and other genetic disorders. The company's proprietary platform utilizes its expertise in RNA-targeted therapeutics and gene editing technologies to develop therapies that address the underlying genetic causes of diseases. Sarepta\u2019s pipeline includes several promising candidates, such as SRP-9001, which aims to provide a transformative treatment for DMD, and a range of other programs targeting rare muscle diseases. The company is committed to patient-centric approaches and collaborates with various stakeholders, including patient advocacy groups, to ensure that the voices of those affected by these conditions are heard and integrated into its development processes. With a robust research and development framework and a commitment to innovation, Sarepta Therapeutics aspires to deliver groundbreaking treatments that improve the lives of patients and their families.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Cambridge, Massachusetts, USA",
    "founded": "1980",
    "website": "https://www.sareptatherapeutics.com",
    "ceo": "Doug Ingram",
    "social_media": {
        "twitter": "https://twitter.com/Sarepta",
        "linkedin": "https://www.linkedin.com/company/sarepta-therapeutics/"
    },
    "investor_relations": "https://investors.sareptatherapeutics.com",
    "key_executives": [
        {
            "name": "Doug Ingram",
            "position": "CEO"
        },
        {
            "name": "Kurt O. Eickhoff",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Gene Therapy",
            "products": [
                "SRP-9001"
            ]
        }
    ],
    "seo": {
        "meta_title": "Sarepta Therapeutics, Inc. | Innovating Gene Therapy for Rare Diseases",
        "meta_description": "Explore Sarepta Therapeutics, Inc., a leader in gene therapy focused on rare diseases like Duchenne muscular dystrophy. Learn about their innovative pipeline and commitment to patient care.",
        "keywords": [
            "Sarepta",
            "Gene Therapy",
            "Duchenne Muscular Dystrophy",
            "Biotechnology",
            "Precision Medicine"
        ]
    },
    "faq": [
        {
            "question": "What is Sarepta Therapeutics focused on?",
            "answer": "Sarepta Therapeutics focuses on developing gene therapies for rare genetic diseases, particularly Duchenne muscular dystrophy."
        },
        {
            "question": "Who is the CEO of Sarepta Therapeutics?",
            "answer": "Doug Ingram is the CEO of Sarepta Therapeutics, Inc."
        },
        {
            "question": "Where is Sarepta headquartered?",
            "answer": "Sarepta is headquartered in Cambridge, Massachusetts, USA."
        },
        {
            "question": "What are some of Sarepta's main products?",
            "answer": "Sarepta's main product in development is SRP-9001, aimed at treating Duchenne muscular dystrophy."
        },
        {
            "question": "When was Sarepta founded?",
            "answer": "Sarepta was founded in 1980."
        }
    ],
    "competitors": [
        "PTCT",
        "BMRN",
        "SRPT"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "VRTX",
        "REGN"
    ]
}